Immuron Ltd — Regulatory Filings 2016

Aug 7, 2016

==> picture [207 x 57] intentionally omitted <==

Travelan to be Stocked by one of the leaders in US Distribution of Work Place Health/OTC Products - Medique Products

Melbourne, Australia, 8 August 2016: Australian microbiome biopharmaceutical company Immuron Limited (ASX: IMC) is pleased to announce that its flagship product Travelan will now be stocked by Medique Products, one of the largest and reputable distributors of health and safety products in the US. Medique has already placed a substantial order to ensure they have enough inventory in-stock to cover the initial expected ramp-up of sales.

Medique Products was founded in 1974 and has built its reputation on its ability to provide the highest quality and safest medical products, including OTC products, to its customers. Over the past several years, Medique has focused on enhancing its competitive advantage by offering increasingly unique products to its distributors which has assisted this organization to achieve consistent year-over-year growth. This has allowed companies, such as Immuron, to quickly penetrate the markets Medique competes in through over 1,000 plus distributor business partners. A key to this success has been the expansion of its dedicated field sales force, where new products are heavily featured and promoted.

Commented, Sean Goodman, Director of Sales:

“Medique Products is excited to partner with Immuron Limited and carry Travelan throughout our network. We believe that the synergy between our two companies will allow us to quickly increase the distribution of the Travelan digestive product into all of our markets including workplace health, correctional Healthcare, School Health and athletic health. We look forward to a long-term partnership with great success.”

Immuron’s US Director of Sales Mr. Travis Robins commented:

“Medique is one of the leaders in the core markets that they serve. What makes Medique unique, is the depth of their many long standing partnerships, their commitment to new products, and the reach of their sales force, which allows for products like Travelan to stay top-of-mind with their customers. We look forward to working closely with Medique’s field sales force and customer service team to educate their many customers about Travelan’s unique value proposition and to drive uptake quickly.”

• • END - -

Company Contact:	Immuron US Investor Relations:
Thomas Liquard	Jon Cunningham
Chief Executive Officer	RedChip Companies, Inc.
AUS Ph: +61 (0)3 9824 5254	US Ph: +1 (407) 644 4256, (ext. 107)
thomasliquard@immuron.com	jon@redchip.com

Suite 1, 1233 High Street www.immuron.com Armadale, Victoria AUSTRALIA 3143 ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

==> picture [76 x 23] intentionally omitted <==

About Immuron

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: http://www.immuron.com/

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Page 2 of 2